BERWYN, PA — Panavance Therapeutics Inc. has shared promising interim findings from its ongoing Phase 1 clinical trial ...

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings ...

The original poster (OP), user My_Alchemy22, shared their story on Reddit, explaining that their aunt is someone who ...

Recurrent urinary tract infections and potentially abnormal Pap smears are among the consequences of untreated GSM.

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

New study examines benefits of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D) using glucagon-like ...